Drug
D1345 | deferoxamine
V
V03AC01 Deferoxamine
[V03AC] Iron chelating agents
[V03A] ALL OTHER THERAPEUTIC PRODUCTS
[V03] ALL OTHER THERAPEUTIC PRODUCTS
[V] Various ATC structures
| Toxicity | Dose | Time | Species | Model | Method | Action | Positive criterion | Reference |
|---|---|---|---|---|---|---|---|---|
| FERROPTOSIS | 100μM | inhibitor | 245 | |||||
| Pictogram | Signal | Statements | Precautionary Statement Codes |
|---|---|---|---|
 |
Warning |
Aggregated GHS information provided by 195 companies from 3 notifications to the ECHA C&L Inventory. H302 (98.97%): Harmful if swallowed [Warning Acute toxicity, oral] Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. |
P264, P270, P301+P312, P330, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.) |
 |
Danger |
Aggregated GHS information provided by 3 companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. Reported as not meeting GHS hazard criteria by 1 of 3 companies. For more detailed information, please visit ECHA C&L website Of the 1 notification(s) provided by 2 of 3 companies with hazard statement code(s): H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation] H317 (100%): May cause an allergic skin reaction [Warning Sensitization, Skin] H319 (100%): Causes serious eye irritation [Warning Serious eye damage/eye irritation] H334 (100%): May cause allergy or asthma symptoms or breathing difficulties if inhaled [Danger Sensitization, respiratory] H335 (100%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposure Respiratory tract irritation] Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. |
P261, P264, P271, P272, P280, P285, P302+P352, P304+P340, P304+P341, P305+P351+P338, P312, P321, P332+P313, P333+P313, P337+P313, P342+P311, P362, P363, P403+P233, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.) |
| Organism | Test type | Route | Dose (normalized dose) | Effect | Source |
|---|---|---|---|---|---|
| child | TDLo | multiple routes | 440mg/kg/6D-I (440mg/kg) | sense organs and special senses: "retinal changes (pigmentary depositions, retinitis, other): eye" | Archives of Disease in Childhood. Vol. 63, Pg. 250, 1988. |
| rat | LD50 | intravenous | 329mg/kg (329mg/kg) | Toxicology and Applied Pharmacology. Vol. 18, Pg. 185, 1971. | |
| rat | LD50 | subcutaneous | 12240mg/kg (12240mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 6, Pg. 119, 1975. | |
| mouse | LD50 | subcutaneous | 1450mg/kg (1450mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 6, Pg. 119, 1975. | |
| mouse | LD50 | oral | 1340mg/kg (1340mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 17, Pg. 748, 1967. | |
| child | TDLo | subcutaneous | 12gm/kg/17W-I (12000mg/kg) | New England Journal of Medicine. Vol. 314, Pg. 869, 1986. | |
| mouse | LD50 | intravenous | 250mg/kg (250mg/kg) | lungs, thorax, or respiration: dyspnea | United States Patent Document. Vol. #4863964, |
| women | TDLo | intravenous | 40mg/kg (40mg/kg) | Nephron. Vol. 46, Pg. 211, 1987. | |
| mouse | LD50 | intraperitoneal | 1680mg/kg (1680mg/kg) | Kiso to Rinsho. Clinical Report. Vol. 4, Pg. 99, 1970. | |
| human | TDLo | subcutaneous | 37gm/kg/2Y-I (37000mg/kg) | sense organs and special senses: optic nerve neuropathy: eye | New England Journal of Medicine. Vol. 314, Pg. 869, 1986. |
| man | TDLo | intravenous | 86mg/kg/1H-C (86mg/kg) | blood: thrombocytopenia | American Journal of Kidney Diseases. Vol. 6, Pg. 254, 1985. |
| 070D519 | 0917AC | 1-Amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetyl hydroxylamino)-6,11,17,22-tetraazaheptaeicosane |
| 15182-EP2316832A1 | 15182-EP2316833A1 | 1950-39-6 |
| 2C10H20N2O3.C5H13N.C3H7NO2 | 3,14,20,25-Pentaazatriacontane-2,10,13,21,24-pentone, 30-amino-3,14,25-trihydroxy- | 3,9,14,20,25-Pentaazatriacontane-2,10,13,21,24-pentone, 30-amino-3,14,25-trihydroxy- |
| 30-Amino-3,14,25-trihydroxy-3,9,14,20,25-pentaazatriacontane-2,10,13,21,24-pentaone | 30-Amino-3,25-trihydroxy-3,9,14,20,25-pentaazatriacontane-2,10,13,21,24-pentaone | 70-51-9 |
| AB00053447 | AB00053447_14 | AKOS016004824 |
| ANW-62156 | AX8233947 | BCP16524 |
| BDBM47715 | BPBio1_000716 | BRD-K09821361-066-05-0 |
| BRD-K09821361-066-06-8 | BRD-K09821361-066-08-4 | BRD-K09821361-066-13-4 |
| BRD-K09821361-066-15-9 | BRD-K09821361-066-16-7 | BRN 2514118 |
| BSPBio_000650 | BSPBio_002131 | Ba 29837 (Salt/Mix) |
| Ba 33112 | Ba-33112 | Butanediamide, N'-(5-((4-((5-(acetylhydroxyamino)pentyl)amino)-1,4-dioxobutyl)hydroxyamino)pentyl)-N-(5-aminopentyl)-N-hydroxy- |
| Butanediamide, N'-[5-[[4-[[5-(acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N-(5-aminopentyl)-N-hydroxy- | Butanediamide,4-dioxobutyl]hydroxyamino]pentyl]-N-(5-aminopentyl)-N-hydroxy- | C06940 |
| C25H48N6O8 | CGH-749B | CHEBI:4356 |
| CHEMBL556 | CTK8B9180 | Cordaneurin |
| D03670 | DB00746 | DEFEROXAMINE, Deferoxamine Mesylate |
| DESFERRIOXAMINE | DF B | DFOA |
| DFOM | DTXSID7022887 | Deferoxamide B |
| Deferoxamin | Deferoxamina | Deferoxamina [INN-Spanish] |
| Deferoxamine (USAN) | Deferoxamine B | Deferoxamine B |
| Deferoxamine [USAN:INN] | Deferoxamine mesilate;Deferoxamine mesylate;N'-[5-[[4-[[5-(acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N-(5-aminopentyl)-N-hydroxysuccinamide monohydrochloride;Deferoxamine;deferoxamine | Deferoxaminum |
| Deferoxaminum [INN-Latin] | Deferriferrioxamine B | Deferrioxamine |
| Deferrioxamine | Deferrioxamine B | Desferal |
| Desferal (Salt/Mix) | Desferan | Desferex |
| Desferin | Desferioxamine B | Desferral |
| Desferriferrioxamin B | Desferrin | Desferrioxamin |
| Desferrioxamine B | DivK1c_000082 | EC 200-738-5 |
| EINECS 200-738-5 | Ferrioxamine B, N-benzoyl- | HMS3604E17 |
| HSDB 3311 | ICL-749B | IDI1_000082 |
| J06Y7MXW4D | KBio1_000082 | KBio2_001372 |
| KBio2_002429 | KBio2_003940 | KBio2_004997 |
| KBio2_006508 | KBio2_007565 | KBio3_001351 |
| KBio3_002908 | KBioGR_000922 | KBioGR_002429 |
| KBioSS_001372 | KBioSS_002435 | LMFA08020169 |
| LS-124964 | MCULE-3095507442 | MLS002702118 |
| N''''-(5-azanylpentyl)-N-[5-[[4-[5-[ethanoyl(oxidanyl)amino]pentylamino]-4-oxidanylidene-butanoyl]-oxidanyl-amino]pentyl]-N''''-oxidanyl-butanediamide;methanesulfonic acid | N'-(5-((4-((5-(Acetylhydroxamino)pentyl)amino)-1,4-dioxobutyl) hydroxyamino)pentyl)-N-(5-aminopentyl)-N-hydroxybutanediamide | N'-[5-(acetyl-hydroxy-amino)pentyl]-N-[5-[3-(5-aminopentyl-hydroxy-carbamoyl)propanoylamino]pentyl]-N-hydroxy-butane diamide |
| N'-{5-[acetyl(hydroxy)amino]pentyl}-N-(5-{4-[(5-aminopentyl)(hydroxy)amino]-4-oxobutanamido}pentyl)-N-hydroxybutanediamide | N'-{5-[acetyl(hydroxy)amino]pentyl}-N-[5-({4-[(5-aminopentyl)(hydroxy)amino]-4-oxobutanoyl}amino)pentyl]-N-hydroxybutanediamide | N-(5-(3-((5-Aminopentyl)hydroxycarbamoyl)propionamido)pentyl)-3-((5-(N-hydroxyacetamido)pentyl)carbamoyl)propionohydroxamic acid |
| N-(5-aminopentyl)-N-hydroxy-N'-[5-(N-hydroxy-3-{[5-(N-hydroxyacetamido)pentyl]carbamoyl}propanamido)pentyl]butanediamide | N-(5-{3-((5-Aminopentyl)hydroxycarbamoyl)propionamido}pentyl)-3-{(5-(N-hydroxyacetamido)pentyl)carbamoyl}propionohydroxamic acid | N-Benzoylferrioxamine B |
| N-[5-(3-[(5-Aminopentyl)hydroxycarbamoyl]propionamido)pentyl]-3-([5-(N-hydroxyacetamido)pentyl]carbamoyl)propionohydroxamic acid | N-[5-[[4-[5-[acetyl(hydroxy)amino]pentylamino]-1,4-dioxobutyl]-hydroxyamino]pentyl]-N''''-(5-aminopentyl)-N''''-hydroxybutanediamide;methanesulfonic acid | N-[5-[[4-[5-[acetyl(hydroxy)amino]pentylamino]-4-keto-butanoyl]-hydroxy-amino]pentyl]-N''-(5-aminopentyl)-N''-hydroxy-succinamide;mesylic acid |
| N-[5-[[4-[5-[acetyl(hydroxy)amino]pentylamino]-4-oxobutanoyl]-hydroxyamino]pentyl]-N''''-(5-aminopentyl)-N''''-hydroxybutanediamide;methanesulfonic acid | N-[5-[[4-[5-[acetyl(hydroxy)amino]pentylamino]-4-oxobutanoyl]-hydroxyamino]pentyl]-N'-(5-aminopentyl)-N'-hydroxybutanediamide | N-benzoyl-Ferrioxamine B |
| N1-(5-Aminopentyl)-N1-hydroxy-N4-(5-(N-hydroxy-4-((5-(N-hydroxyacetamido)pentyl)amino)-4-oxobutanamido)pentyl)succinamide | NCGC00178802-01 | NCGC00178802-02 |
| NCGC00178802-03 | NCI60_002181 | NINDS_000082 |
| NS00007870 | NSC-527604 | NSC268993 |
| NSC527604 | NSC644468 | N~1~-(5-(Acetyl(hydroxy)amino)pentyl)-N~4~-(5-((4-((5-aminopentyl)(hydroxy)amino)-4-oxobutanoyl)amino)pentyl)-N~4~-hydroxysuccinamide |
| N~4~-{5-[Acetyl(hydroxy)amino]pentyl}-N~1~-(5-{4-[(5-aminopentyl)(hydroxy)amino]-4-oxobutanamido}pentyl)-N~1~-hydroxybutanediamide | Perineurin | Prestwick0_000725 |
| Prestwick1_000725 | Prestwick2_000725 | Prestwick3_000725 |
| Propionohydroxamic acid, N-(5-(3-((5-aminopentyl)hydroxycarbamoyl)propionamido)pentyl)-3-((5-(N-hydroxyacetamido)pentyl)carbamoyl)- | Propionohydroxamic acid, N-[5-(3-[(5-aminopentyl)hydroxycarbamoyl]propionamido)phentyl]-3-([5-(N-hydroxyacetamido)pentyl]carbamoyl)- | Propionohydroxamic acid, N-[5-[3-[(5-aminopentyl)hydroxycarbamoyl]propionamido]pentyl]-3-[(5-N-hydroxyacetamido)pentyl]carbamoyl]- |
| Propionohydroxamic acid, N-[5-[3-[(5-aminopentyl)hydroxycarbamoyl]propionamido]pentyl]-3-[[5-(N-hydroxyacetamido)pentyl]carbamoyl]- | Q-200933 | Q419618 |
| SBI-0051332.P003 | SCHEMBL34571 | SMP2_000121 |
| SMR000058548 | SMR001550278 | SPBio_001109 |
| SPBio_002589 | Spectrum2_001155 | Spectrum3_000376 |
| Spectrum4_000311 | Spectrum5_000827 | Spectrum_000892 |
| UNII-J06Y7MXW4D | WLN: Z5NQV/2VM5NQV/ 21 | ZINC3830635 |
| cMAP_000047 | cid_62881 | deferoxamine |
| desferrioxamine-B |